Vir Biotechnology (NASDAQ:VIR) CAO Sells $11,918.70 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,530 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $7.79, for a total value of $11,918.70. Following the sale, the chief accounting officer directly owned 47,872 shares in the company, valued at approximately $372,922.88. This trade represents a 3.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Vir Biotechnology Trading Down 3.3%

Vir Biotechnology stock opened at $7.56 on Friday. The stock has a 50-day moving average price of $6.73 and a two-hundred day moving average price of $5.92. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $9.93. The company has a market capitalization of $1.05 billion, a PE ratio of -2.09 and a beta of 1.69.

Analyst Ratings Changes

Several analysts recently weighed in on VIR shares. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research note on Monday, February 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Barclays set a $26.00 price target on Vir Biotechnology in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $16.29.

Institutional Trading of Vir Biotechnology

A number of large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after purchasing an additional 1,390 shares during the period. CWM LLC increased its holdings in Vir Biotechnology by 23.0% in the fourth quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after purchasing an additional 1,646 shares in the last quarter. ProShare Advisors LLC lifted its stake in Vir Biotechnology by 7.8% in the fourth quarter. ProShare Advisors LLC now owns 23,525 shares of the company’s stock valued at $142,000 after buying an additional 1,705 shares during the period. Clarius Group LLC lifted its stake in Vir Biotechnology by 0.3% in the third quarter. Clarius Group LLC now owns 619,312 shares of the company’s stock valued at $3,536,000 after buying an additional 1,777 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Vir Biotechnology by 1.0% during the 2nd quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock worth $1,154,000 after buying an additional 2,300 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.